Lexicon Pharma Reports Exit/Disposal Costs
Ticker: LXRX · Form: 8-K · Filed: Nov 22, 2024
Sentiment: neutral
Topics: restructuring, disposal, 8-K
Related Tickers: LXRX
TL;DR
Lexicon Pharma (LXRX) filed an 8-K for exit/disposal costs as of Nov 22, 2024.
AI Summary
Lexicon Pharmaceuticals, Inc. filed an 8-K on November 22, 2024, to report on costs associated with exit or disposal activities. The filing does not specify the exact dollar amounts or the nature of the exit/disposal activities, but it indicates that these events occurred as of November 22, 2024.
Why It Matters
This filing signals potential restructuring or discontinuation of certain operations within Lexicon Pharmaceuticals, which could impact future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates potential restructuring or discontinuation of operations, which carries inherent business risks.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- November 22, 2024 (date) — Date of Report
FAQ
What specific activities are associated with the exit or disposal?
The filing does not specify the nature of the exit or disposal activities.
What is the total financial impact of these exit or disposal activities?
The filing does not disclose specific dollar amounts related to the costs associated with exit or disposal activities.
When did these exit or disposal activities commence or become effective?
The filing indicates that the activities are as of November 22, 2024.
Is this related to a specific product or division of Lexicon Pharmaceuticals?
The filing does not provide details on which specific product or division these activities pertain to.
Are there any expected future implications from these exit or disposal activities?
The filing does not detail any expected future implications.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-11-22 16:05:13
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
- $9.0 million — ill incur an aggregate of approximately $9.0 million to $10.5 million in pre-tax charges in
- $10.5 million — regate of approximately $9.0 million to $10.5 million in pre-tax charges in connection with s
Filing Documents
- lxrx-20241122.htm (8-K) — 21KB
- 0001062822-24-000064.txt ( ) — 140KB
- lxrx-20241122.xsd (EX-101.SCH) — 2KB
- lxrx-20241122_lab.xml (EX-101.LAB) — 21KB
- lxrx-20241122_pre.xml (EX-101.PRE) — 12KB
- lxrx-20241122_htm.xml (XML) — 3KB
05 Costs Associated with Exit or Disposal Activities
Item 2.05 Costs Associated with Exit or Disposal Activities. Following our receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug Administration regarding our New Drug Application for ZYNQUISTA (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease, on November 22, 2024 we determined to eliminate our commercial operations and rationalize resources across all functions in order to preserve cash and focus our resources on advancing our clinical development pipeline. In connection with such determination, we intend to implement a reduction in force which will reduce our workforce by approximately sixty percent. We estimate that we will incur an aggregate of approximately $9.0 million to $10.5 million in pre-tax charges in connection with severance and other employee costs associated with the reduction in force, most of which will be paid in the first quarter of 2025 and all of which are expected to be cash expenditures.
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: November 22, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel